Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the regulator
IQ-AI Ltd () said it has received the regulatory green light in America for its StoneChecker software, which is used to assess kidney stones.
Imaging Biometrics, the company’s Milwaukee-based subsidiary, was granted “clearance to market” by the US Food & Drug Administration.
The company said it would issue an update outlining the scale of the opportunity along with its product roll-out plans in the next few days.
IQ-AI shares surged 41% to 6.65p on Friday morning.
-- Adds shares price --
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE